View Item 

Show simple item record

Consensus recommendations in the management of Ewing sarcoma from the National Ewing Sarcoma Tumor Board
dc.contributor.authorGupta, Ajay
dc.contributor.authorRiedel, Richard F.
dc.contributor.authorShah, Chirag
dc.contributor.authorBorinstein, Scott C.
dc.contributor.authorIsakoff, Michael S.
dc.contributor.authorChugh, Rashmi
dc.contributor.authorRosenblum, Jeremy M.
dc.contributor.authorMurphy, Erin S.
dc.contributor.authorCampbell, Shauna R.
dc.contributor.authorAlbert, Catherine M.
dc.contributor.authorZahler, Stacey
dc.contributor.authorThomas, Stefanie M.
dc.contributor.authorTrucco, Matteo
dc.date.accessioned2023-11-06T16:34:42Z
dc.date.available2024-12-06 11:34:41en
dc.date.available2023-11-06T16:34:42Z
dc.date.issued2023-11-01
dc.identifier.citationGupta, Ajay; Riedel, Richard F.; Shah, Chirag; Borinstein, Scott C.; Isakoff, Michael S.; Chugh, Rashmi; Rosenblum, Jeremy M.; Murphy, Erin S.; Campbell, Shauna R.; Albert, Catherine M.; Zahler, Stacey; Thomas, Stefanie M.; Trucco, Matteo (2023). "Consensus recommendations in the management of Ewing sarcoma from the National Ewing Sarcoma Tumor Board." Cancer 129(21): 3363-3371.
dc.identifier.issn0008-543X
dc.identifier.issn1097-0142
dc.identifier.urihttps://hdl.handle.net/2027.42/191364
dc.description.abstractEwing sarcoma (ES) is a malignant tumor of bone and soft tissue that most often occurs in adolescents and young adults. Despite an international coordinated approach, several nuances, discrepancies, and debates remain in defining the standard of care for treating ES. In this review, the authors leverage the expertise assembled by formation of the National Ewing Sarcoma Tumor Board, a multi-institution, multidisciplinary virtual tumor board that meets monthly to discuss complicated and challenging cases of ES. This report is focused on select topics that apply to the management of patients with newly diagnosed ES. The specific topics covered include indications for bone marrow aspirate and biopsy for initial evaluation compared with fluorodeoxyglucose-positron emission tomography, the role of interval compressed chemotherapy in patients aged 18 years and older, the role of adding ifosfamide/etoposide to vincristine/doxorubicin/cyclophosphamide for patients with metastatic disease, the data on and role of high-dose chemotherapy with autologous stem cell transplantation, maintenance therapy, and whole-lung irradiation. The data referenced are often limited to subgroup analyses and/or compiled from multiple sources. Although not intended to replace the clinical judgement of treating physicians, the guidelines are intended to provide clarity and recommendations for the upfront management of patients with ES.Plain Language SummaryEwing sarcoma is a malignant tumor of bone and soft tissue that most often occurs in adolescents and young adults.For this review, the authors used the experience of the National Ewing Sarcoma Tumor Board, a multi-institution, multidisciplinary virtual tumor board that meets monthly to discuss complicated and challenging cases of Ewing sarcoma.Although not intended to replace the clinical judgement of treating physicians, the guidelines will focus on the development of consensus statements for the upfront management of patients with Ewing sarcoma.Debates remain in defining the standard of care for treating Ewing sarcoma. This set of consensus statements from the National Ewing Sarcoma Tumor Board is intended to provide clarity and recommendations for the upfront management of these patients.
dc.publisherWiley Periodicals, Inc.
dc.subject.otherstem cell transplantation
dc.subject.otherEwing sarcoma
dc.subject.othermetastasis
dc.subject.otherneoadjuvant therapy
dc.subject.otheradjuvant chemoradiotherapy
dc.subject.otherconsensus
dc.titleConsensus recommendations in the management of Ewing sarcoma from the National Ewing Sarcoma Tumor Board
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbsecondlevelPublic Health
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/191364/1/cncr34942_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/191364/2/cncr34942.pdf
dc.identifier.doi10.1002/cncr.34942
dc.identifier.sourceCancer
dc.identifier.citedreferencePasquier E, Kavallaris M, Andre N. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol. 2010; 7 ( 8 ): 455 - 465. doi: 10.1038/nrclinonc.2010.82
dc.identifier.citedreferencePawlowska AB, Sun V, Calvert GT, et al. Long-term follow-up of high-dose chemotherapy with autologous stem cell transplantation in children and young adults with metastatic or relapsed Ewing sarcoma: a single-institution experience. Transplant Cell Ther. 2021; 27 ( 1 ): 72.e1 - 72.e7. doi: 10.1016/j.bbmt.2020.09.029
dc.identifier.citedreferenceTenneti P, Zahid U, Iftikhar A, et al. Role of high-dose chemotherapy and autologous hematopoietic cell transplantation for children and young adults with relapsed Ewing’s sarcoma: a systematic review. Sarcoma. 2018; 2018: 2640674. doi: 10.1155/2018/2640674
dc.identifier.citedreferenceMcTiernan A, Driver D, Michelagnoli MP, Kilby AM, Whelan JS. High dose chemotherapy with bone marrow or peripheral stem cell rescue is an effective treatment option for patients with relapsed or progressive Ewing’s sarcoma family of tumours. Ann Oncol. 2006; 17 ( 8 ): 1301 - 1305. doi: 10.1093/annonc/mdl108
dc.identifier.citedreferenceRasper M, Jabar S, Ranft A, Jürgens H, Amler S, Dirksen U. The value of high-dose chemotherapy in patients with first relapsed Ewing sarcoma. Pediatr Blood Cancer. 2014; 61 ( 8 ): 1382 - 1386. doi: 10.1002/pbc.25042
dc.identifier.citedreferenceBarker LM, Pendergrass TW, Sanders JE, Hawkins DS. Survival after recurrence of Ewing’s sarcoma family of tumors. J Clin Oncol. 2005; 23 ( 19 ): 4354 - 4362. doi: 10.1200/JCO.2005.05.105
dc.identifier.citedreferenceBacci G, Ferrari S, Longhi A, et al. Therapy and survival after recurrence of Ewing’s tumors: the Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997. Ann Oncol. 2003; 14 ( 11 ): 1654 - 1659. doi: 10.1093/annonc/mdg457
dc.identifier.citedreferenceFerrari S, Sundby Hall K, Luksch R, et al. Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol. Ann Oncol. 2011; 22 ( 5 ): 1221 - 1227. doi: 10.1093/annonc/mdq573
dc.identifier.citedreferenceKushner BH, Meyers PA. How effective is dose-intensive/myeloablative therapy against Ewing’s sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan Kettering experience and a literature review. J Clin Oncol. 2001; 19 ( 3 ): 870 - 880. doi: 10.1200/jco.2001.19.3.870
dc.identifier.citedreferenceWhelan J, Le Deley MC, Dirksen U, et al. High-dose chemotherapy and blood autologous stem-cell rescue compared with standard chemotherapy in localized high-risk Ewing sarcoma: results of Euro-E.W.I.N.G.99 and Ewing-2008. J Clin Oncol. 2018; 36 ( 31 ): 3110 - 3119. doi: 10.1200/jco.2018.78.2516
dc.identifier.citedreferenceDirksen U, Brennan B, Le Deley MC, et al. High-dose chemotherapy compared with standard chemotherapy and lung radiation in Ewing sarcoma with pulmonary metastases: results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008. J Clin Oncol. 2019; 37 ( 34 ): 3192 - 3202. doi: 10.1200/jco.19.00915
dc.identifier.citedreferenceKoch R, Gelderblom H, Haveman L, et al. High-dose treosulfan and melphalan as consolidation therapy versus standard therapy for high-risk (metastatic) Ewing sarcoma. J Clin Oncol. 2022; 40 ( 21 ): 2307 - 2320. doi: 10.1200/jco.21.01942
dc.identifier.citedreferenceLuksch R, Milano GM, Barretta F, et al. Efficacy of dose intensification in induction therapy for localized Ewing sarcoma: Italian Sarcoma Group (ISG) and Associazione Italiana Ematologia ed Oncologia Pediatrica (AIEOP) ISG/AIEOP EW-1 study [abstract]. J Clin Oncol. 2021; 39 ( 15 suppl ): 11501. doi: 10.1200/JCO.2021.39.15_suppl.11501
dc.identifier.citedreferenceGorlick R, Janeway KA, Adamson PC. Dose intensification improves the outcome of Ewing sarcoma. J Clin Oncol. 2018; 36 ( 31 ): 3072 - 3073. doi: 10.1200/JCO.2018.79.3489
dc.identifier.citedreferenceBrennan B, Kirton L, Marec-Bérard P, et al. Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial. Lancet. 2022; 400 ( 10362 ): 1513 - 1521. doi: 10.1016/S0140-6736(22)01790-1
dc.identifier.citedreferenceMeyers PA, Ambati SR, Slotkin EK, Cruz FD, Wexler LH. The addition of cycles of irinotecan/temozolomide (i/T) to cycles of vincristine, doxorubicin, cyclophosphamide (VDC) and cycles of ifosfamide, etoposide (IE) for the treatment of Ewing sarcoma (ES) [abstract]. J Clin Oncol. 2018; 36 ( 15 suppl ): 10533. doi: 10.1200/JCO.2018.36.15_suppl.10533
dc.identifier.citedreferenceRichey SL, Rao P, Wood CG, Patel S, Tannir NM. Metastatic extraosseous Ewing’s sarcoma (EES)/primitive neuroectodermal tumor (PNET) of the kidney: 8-year durable response after induction and maintenance chemotherapy. Clin Genitourin Cancer. 2012; 10 ( 3 ): 210 - 212. doi: 10.1016/j.clgc.2012.03.004
dc.identifier.citedreferenceTamura A, Yamamoto N, Nino N, et al. Pazopanib maintenance therapy after tandem high-dose chemotherapy for disseminated Ewing sarcoma. Int Cancer Conf J. 2019; 8 ( 3 ): 95 - 100. doi: 10.1007/s13691-019-00362-w
dc.identifier.citedreferenceBisogno G, De Salvo GL, Bergeron C, et al. Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2019; 20 ( 11 ): 1566 - 1575. doi: 10.1016/s1470-2045(19)30617-5
dc.identifier.citedreferenceKoscielniak E, Sparber-Sauer M, Scheer M, et al. Extraskeletal Ewing sarcoma in children, adolescents, and young adults. An analysis of three prospective studies of the Cooperative Weichteilsarkomstudiengruppe (CWS). Pediatr Blood Cancer. 2021; 68 ( 10 ): e29145. doi: 10.1002/pbc.29145
dc.identifier.citedreferenceRaciborska A, Bilska K, Rodriguez-Galindo C. Maintenance treatment with trofosfamide in patients with primary bone Ewing sarcoma—single center experience. Dev Period Med. 2019; 23: 39 - 44. doi: 10.34763/devperiodmed.20192301.3944
dc.identifier.citedreferenceMargolis LW, Phillips TL. Whole-lung irradiation for metastatic tumor. Radiology. 1969; 93 ( 5 ): 1173 - 1179. doi: 10.1148/93.5.1173
dc.identifier.citedreferencePaulussen M, Ahrens S, Burdach S, et al. Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. Ann Oncol. 1998; 9 ( 3 ): 275 - 281. doi: 10.1023/a:1008208511815
dc.identifier.citedreferencePaulussen M, Ahrens S, Craft AW, et al. Ewing’s tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing’s Sarcoma Studies patients. J Clin Oncol. 1998; 16 ( 9 ): 3044 - 3052. doi: 10.1200/jco.1998.16.9.3044
dc.identifier.citedreferenceLuksch R, Tienghi A, Hall KS, et al. Primary metastatic Ewing’s family tumors: results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSG IV Study including myeloablative chemotherapy and total-lung irradiation. Ann Oncol. 2012; 23 ( 11 ): 2970 - 2976. doi: 10.1093/annonc/mds117
dc.identifier.citedreferenceCasey DL, Alektiar KM, Gerber NK, Wolden SL. Whole lung irradiation for adults with pulmonary metastases from Ewing sarcoma. Int J Radiat Oncol Biol Phys. 2014; 89 ( 5 ): 1069 - 1075. doi: 10.1016/j.ijrobp.2014.04.036
dc.identifier.citedreferenceRonchi L, Buwenge M, Cortesi A, et al. Whole lung irradiation in patients with osteosarcoma and Ewing sarcoma. Anticancer Res. 2018; 38 ( 9 ): 4977 - 4985. doi: 10.21873/anticanres.12816
dc.identifier.citedreferenceScobioala S, Eich HT. Risk stratification of pulmonary toxicities in the combination of whole lung irradiation and high-dose chemotherapy for Ewing sarcoma patients with lung metastases: a review. Strahlenther Onkol. 2020; 196 ( 6 ): 495 - 504. doi: 10.1007/s00066-020-01599-8
dc.identifier.citedreferenceBolling T, Schuck A, Paulussen M, et al. Whole lung irradiation in patients with exclusively pulmonary metastases of Ewing tumors. Toxicity analysis and treatment results of the EICESS-92 trial. Strahlenther Onkol. 2008; 184 ( 4 ): 193 - 197. doi: 10.1007/s00066-008-1810-x
dc.identifier.citedreferenceAbate ME, Cammelli S, Ronchi L, et al. Whole lung irradiation after high-dose busulfan/melphalan in Ewing sarcoma with lung metastases: an Italian Sarcoma Group and Associazione Italiana Ematologia Oncologia Pediatrica joint study. Cancers (Basel). 2021; 13 ( 11 ): 2789. doi: 10.3390/cancers13112789
dc.identifier.citedreferenceTanguturi SK, George S, Marcus KJ, Demetri GD, Baldini EH. Whole lung irradiation in adults with metastatic Ewing sarcoma: practice patterns and implications for treatment. Sarcoma. 2015; 2015: 591698. doi: 10.1155/2015/591698
dc.identifier.citedreferenceBosarge CL, Ewing MM, DesRosiers CM, Buchsbaum JC. A dosimetric comparison of whole-lung treatment techniques in the pediatric population. Med Dosim. 2016; 41 ( 2 ): 126 - 130. doi: 10.1016/j.meddos.2015.10.006
dc.identifier.citedreferenceKalapurakal JA, Gopalakrishnan M, Walterhouse DO, et al. Cardiac-sparing whole lung IMRT in patients with pediatric tumors and lung metastasis: final report of a prospective multicenter clinical trial. Int J Radiat Oncol Biol Phys. 2019; 103 ( 1 ): 28 - 37. doi: 10.1016/j.ijrobp.2018.08.034
dc.identifier.citedreferenceBaumann BC, Nagda SN, Kolker JD, et al. Efficacy and safety of stereotactic body radiation therapy for the treatment of pulmonary metastases from sarcoma: a potential alternative to resection. J Surg Oncol. 2016; 114 ( 1 ): 65 - 69. doi: 10.1002/jso.24268
dc.identifier.citedreferenceElledge CR, Krasin MJ, Ladra MM, et al. A multi-institutional phase 2 trial of stereotactic body radiotherapy in the treatment of bone metastases in pediatric and young adult patients with sarcoma. Cancer. 2021; 127 ( 5 ): 739 - 747. doi: 10.1002/cncr.33306
dc.identifier.citedreferenceCederberg KB, Iyer RS, Chaturvedi A, et al. Imaging of pediatric bone tumors: a COG Diagnostic Imaging Committee/SPR Oncology Committee white paper. Pediatr Blood Cancer. 2023; 70 ( suppl 4 ): e30000. doi: 10.1002/pbc.30000
dc.identifier.citedreferenceThiel U, Wawer A, von Luettichau I, et al. Bone marrow involvement identifies a subgroup of advanced Ewing sarcoma patients with fatal outcome irrespective of therapy in contrast to curable patients with multiple bone metastases but unaffected marrow. Oncotarget. 2016; 7 ( 43 ): 70959 - 70968. doi: 10.18632/oncotarget.10938
dc.identifier.citedreferenceCampbell KM, Shulman DS, Grier HE, DuBois SG. Role of bone marrow biopsy for staging new patients with Ewing sarcoma: a systematic review. Pediatr Blood Cancer. 2021; 68 ( 2 ): e28807. doi: 10.1002/pbc.28807
dc.identifier.citedreferenceKopp LM, Hu C, Rozo B, et al. Utility of bone marrow aspiration and biopsy in initial staging of Ewing sarcoma. Pediatr Blood Cancer. 2015; 62 ( 1 ): 12 - 15. doi: 10.1002/pbc.25212
dc.identifier.citedreferenceNewman EN, Jones RL, Hawkins DS. An evaluation of [F-18]-fluorodeoxy-D-glucose positron emission tomography, bone scan, and bone marrow aspiration/biopsy as staging investigations in Ewing sarcoma. Pediatr Blood Cancer. 2013; 60 ( 7 ): 1113 - 1117. doi: 10.1002/pbc.24406
dc.identifier.citedreferenceCesari M, Righi A, Colangeli M, et al. Bone marrow biopsy in the initial staging of Ewing sarcoma: experience from a single institution. Pediatr Blood Cancer. 2019; 66 ( 6 ): e27653. doi: 10.1002/pbc.27653
dc.identifier.citedreferenceGuinot A, Tabone-Eglinger S, Isnardi V, et al. Staging of newly diagnosed Ewing sarcoma: results of bone marrow aspiration and biopsy versus (18)FDG-PET/CT imaging for bone marrow involvement. Eur J Cancer. 2023; 179: 56 - 64. doi: 10.1016/j.ejca.2022.11.002
dc.identifier.citedreferenceIngley KM, Wan S, Vöö S, et al. Is it time to call time on bone marrow biopsy for staging Ewing sarcoma (ES)? Cancers (Basel). 2021; 13: 3261. doi: 10.3390/cancers13133261
dc.identifier.citedreferenceSeth N, Seth I, Bulloch G, et al. [18]F-FDG PET and PET/CT as a diagnostic method for Ewing sarcoma: a systematic review and meta-analysis. Pediatr Blood Cancer. 2022; 69 ( 3 ): e29415. doi: 10.1002/pbc.29415
dc.identifier.citedreferenceTal AL, Doshi H, Parkar F, et al. The utility of 18FDG PET/CT versus bone scan for identification of bone metastases in a pediatric sarcoma population and a review of the literature. J Pediatr Hematol Oncol. 2021; 43 ( 2 ): 52 - 58. doi: 10.1097/mph.0000000000001917
dc.identifier.citedreferencePadwal J, Baratto L, Chakraborty A, et al. PET/MR of pediatric bone tumors: what the radiologist needs to know. Skel Radiol. 2022; 52 ( 3 ): 315 - 328. doi: 10.1007/s00256-022-04113-6
dc.identifier.citedreferenceFarina A, Gasperini C, Aparisi Gómez MP, Bazzocchi A, Fanti S, Nanni C. The role of FDG-PET and whole-body MRI in high grade bone sarcomas with particular focus on osteosarcoma. Semin Nucl Med. 2022; 52 ( 5 ): 635 - 646. doi: 10.1053/j.semnuclmed.2021.10.001
dc.identifier.citedreferenceOrsatti G, Zucchetta P, Varotto A, et al. Volumetric histograms-based analysis of apparent diffusion coefficients and standard uptake values for the assessment of pediatric sarcoma at staging: preliminary results of a PET/MRI study. Radiol Med. 2021; 126 ( 6 ): 878 - 885. doi: 10.1007/s11547-021-01340-0
dc.identifier.citedreferenceKumar J, Seith A, Kumar A, et al. Whole-body MR imaging with the use of parallel imaging for detection of skeletal metastases in pediatric patients with small-cell neoplasms: comparison with skeletal scintigraphy and FDG PET/CT. Pediatr Radiol. 2008; 38 ( 9 ): 953 - 962. doi: 10.1007/s00247-008-0921-y
dc.identifier.citedreferenceHuang R, Han D, Shi C, et al. Construction and validation of nomograms for non-metastatic Ewing sarcoma: a prognostic factor analysis based on the SEER database. Oncol Lett. 2021; 22 ( 5 ): 777. doi: 10.3892/ol.2021.13038
dc.identifier.citedreferenceWomer RB, Daller RT, Fenton JG, Miser JS. Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing’s sarcomas and soft tissue sarcomas in children. Eur J Cancer. 2000; 36 ( 1 ): 87 - 94. doi: 10.1016/s0959-8049(99)00236-1
dc.identifier.citedreferenceWomer RB, West DC, Krailo MD, et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children’s Oncology Group. J Clin Oncol. 2012; 30 ( 33 ): 4148 - 4154. doi: 10.1200/JCO.2011.41.5703
dc.identifier.citedreferenceCash T, Krailo MD, Buxton A, et al. Long-term outcomes in patients with localized Ewing sarcoma treated with interval-compressed chemotherapy: a long-term follow-up report from Children’s Oncology Group study AEWS0031 [abstract]. J Clin Oncol. 2022; 40 ( 16 suppl ): 11505. doi: 10.1200/JCO.2022.40.16_suppl.11505
dc.identifier.citedreferenceWhelan J, Khan A, Sharma A, et al. Interval compressed vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide, etoposide in patients with advanced Ewing’s and other small round cell sarcomas. Clin Sarcoma Res. 2012; 2 ( 1 ): 12. doi: 10.1186/2045-3329-2-12
dc.identifier.citedreferenceLu E, Ryan CW, Bassale S, Lim JY, Davis LE. Feasibility of treating adults with Ewing or Ewing-like sarcoma with interval-compressed vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etoposide. Oncologist. 2020; 25 ( 2 ): 150 - 155. doi: 10.1634/theoncologist.2019-0532
dc.identifier.citedreferenceShankar AG, Ashley S, Craft AW, Pinkerton CR. Outcome after relapse in an unselected cohort of children and adolescents with Ewing sarcoma. Med Pediatr Oncol. 2003; 40 ( 3 ): 141 - 147. doi: 10.1002/mpo.10248
dc.identifier.citedreferenceLeavey PJ, Laack NN, Krailo MD, et al. Phase III trial adding vincristine-topotecan-cyclophosphamide to the initial treatment of patients with nonmetastatic Ewing sarcoma: a Children’s Oncology Group report. J Clin Oncol. 2021; 39 ( 36 ): 4029 - 4038. doi: 10.1200/jco.21.00358
dc.identifier.citedreferenceGupta AA, Pappo A, Saunders N, et al. Clinical outcome of children and adults with localized Ewing sarcoma: impact of chemotherapy dose and timing of local therapy. Cancer. 2010; 116 ( 13 ): 3189 - 3194. doi: 10.1002/cncr.25144
dc.identifier.citedreferenceJagodzińska-Mucha P, Ługowska I, Świtaj T, et al. The clinical prognostic factors and treatment outcomes of adult patients with Ewing sarcoma. Int J Clin Oncol. 2020; 25 ( 11 ): 2006 - 2014. doi: 10.1007/s10147-020-01741-7
dc.identifier.citedreferenceZhang J, Huang Y, Sun Y, et al. Impact of chemotherapy cycles and intervals on outcomes of nonspinal Ewing sarcoma in adults: a real-world experience. BMC Cancer. 2019; 19 ( 1 ): 1168. doi: 10.1186/s12885-019-6407-5
dc.identifier.citedreferenceGrier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003; 348 ( 8 ): 694 - 701. doi: 10.1056/NEJMoa020890
dc.identifier.citedreferenceMagrath I, Sandlund J, Raynor A, Rosenberg S, Arasi V, Miser J. A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people. Cancer Chemother Pharmacol. 1986; 18 ( suppl 2 ): S25 - S28. doi: 10.1007/bf00647446
dc.identifier.citedreferenceMiser JS, Kinsella TJ, Triche TJ, et al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol. 1987; 5 ( 8 ): 1191 - 1198. doi: 10.1200/jco.1987.5.8.1191
dc.identifier.citedreferenceKushner BH, Meyers PA, Gerald WL, et al. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing’s sarcoma, in children and young adults. J Clin Oncol. 1995; 13 ( 11 ): 2796 - 2804. doi: 10.1200/jco.1995.13.11.2796
dc.identifier.citedreferenceKolb EA, Kushner BH, Gorlick R, et al. Long-term event-free survival after intensive chemotherapy for Ewing’s family of tumors in children and young adults. J Clin Oncol. 2003; 21 ( 18 ): 3423 - 3430. doi: 10.1200/JCO.2003.10.033
dc.identifier.citedreferenceBernstein ML, Devidas M, Lafreniere D, et al. Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children’s Cancer Group Phase II Study 9457—a report from the Children’s Oncology Group. J Clin Oncol. 2006; 24 ( 1 ): 152 - 159. doi: 10.1200/JCO.2005.02.1717
dc.identifier.citedreferenceMiser JS, Goldsby RE, Chen Z, et al. Treatment of metastatic Ewing sarcoma/primitive neuroectodermal tumor of bone: evaluation of increasing the dose intensity of chemotherapy—a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2007; 49 ( 7 ): 894 - 900. doi: 10.1002/pbc.21233
dc.identifier.citedreferenceFelgenhauer JL, Nieder ML, Krailo MD, et al. A pilot study of low-dose anti-angiogenic chemotherapy in combination with standard multiagent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma family of tumors: a Children’s Oncology Group (COG) phase II study NCT00061893. Pediatr Blood Cancer. 2013; 60 ( 3 ): 409 - 414. doi: 10.1002/pbc.24328
dc.identifier.citedreferenceDuBois SG, Krailo MD, Glade-Bender J, et al. Randomized phase III trial of ganitumab with interval-compressed chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma: a report from the Children’s Oncology Group. J Clin Oncol. 2023; 41 ( 11 ): 2098 - 2107. doi: 10.1200/jco.22.01815
dc.identifier.citedreferenceMiser JS, Krailo MD, Tarbell NJ, et al. Treatment of metastatic Ewing’s sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide—a Children’s Cancer Group and Pediatric Oncology Group study. J Clin Oncol. 2004; 22 ( 14 ): 2873 - 2876. doi: 10.1200/JCO.2004.01.041
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cncr34942_am.pdf
Size:
674.9KB
Format:
PDF
View/Open
Name:
cncr34942.pdf
Size:
327.2KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe its collections in a way that respects the people and communities who create, use, and are represented in them. We encourage you to Contact Us anonymously if you encounter harmful or problematic language in catalog records or finding aids. More information about our policies and practices is available at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.